Phase 3 Randomized, Controlled Trial of Switching to Fixed-dose Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Boosted Protease Inhibitor-based Regimens in Virologically Suppressed Adults: Week 48 Results.
published in: Open Forum Infectious Diseases
date of publication: 2017-10-04
main subject: virology, phase III clinical trial, tenofovir, emtricitabine
Cites articles
There is nothing here
Article - wd:Q47149347